Risk estimations and treatment decisions in early stage breast cancer: Agreement among oncologists and the impact of the 70-gene signature

European Journal of Cancer

Volumn 50, Issue 6, 2014, Pages 1045-1054

  Drukker, C A ^a   Van Den Hout, H C ^a   Sonke, G S ^a   Brain, E ^b   Bonnefoi, H ^c   Cardoso, F ^d   Goldhirsch, A ^e   Harbeck, N ^f   Honkoop, A H ^g   Koornstra, R H T ^h   Van Laarhoven, H W M ⁱ   Portielje, J E A ^j   Schneeweiss, A ^k   Smorenburg, C H ^l   Stouthard, J ^a   Linn, S C ^a   Schmidt, M K ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b INSTITUT CURIE   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d Champalimaud Cancer Centre   (Portugal)

^e EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^f UNIVERSITY OF MUNICH   (Germany)

^g Isala Klinieken ^*  (Netherlands)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY OF AMSTERDAM   (Netherlands)

^j HAGA HOSPITAL   (Netherlands)

^k UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^l Location Alkmaar   (Netherlands)

more..

Author keywords

70 gene signature; Adjuvant systemic therapy; Breast cancer; Clinical decision making; Risk estimation

Indexed keywords

TRASTUZUMAB;

70 GENE SIGNATURE; ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RISK; CANCER STAGING; CLINICAL ARTICLE; CLINICAL DECISION MAKING; DNA MICROARRAY; HUMAN; MIDDLE AGED; ONCOLOGIST; PRIORITY JOURNAL; QUESTIONNAIRE; RECURRENCE RISK;

70-GENE SIGNATURE; ADJUVANT SYSTEMIC THERAPY; BREAST CANCER; CLINICAL DECISION-MAKING; RISK ESTIMATION;

ADULT; AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DECISION MAKING; EARLY DETECTION OF CANCER; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEDICAL ONCOLOGY; MIDDLE AGED; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS;

EID: 84897865171     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.01.016     Document Type: Article

References (21)

1. J.M. Bueno-de-Mesquita, G.S. Sonke, M.J. van de Vijver, and S.C. Linn Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice Ann Oncol 22 2011 2021 2030
2. M.J. van de Vijver, Y.D. He, and L.J. van 't Veer et al. A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 347 2002 1999 2009
3. Integraal Kankercentrum Nederland: NABON richtlijn mammacarcinoom; 2012.
4. F. Cardoso Microarray technology and its effect on breast cancer (re)classification and prediction of outcome Breast Cancer Res 5 2003 303 304
5. F. Cardoso, L. van 't Veer, E. Rutgers, S. Loi, S. Mook, and M.J. Piccart-Gebhart Clinical application of the 70-gene profile: the MINDACT trial J Clin Oncol 26 2008 729 735
6. G. D'Eredita', C. Giardina, M. Martellotta, T. Natale, and F. Ferrarese Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution Eur J Cancer 37 2001 591 596
7. A. Goldhirsch, J.H. Glick, R.D. Gelber, A.S. Coates, and H.J. Senn Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer J Clin Oncol 19 2001 3817 3827
8. I.A. Olivotto, C.D. Bajdik, and P.M. Ravdin et al. Population-based validation of the prognostic model ADJUVANT! For early breast cancer J Clin Oncol 23 2005 2716 2725
9. H.A. Azim Jr., S. Michiels, and F. Zagouri et al. Utility of prognostic genomic tests in breast cancer practice: the IMPAKT 2012 Working Group Consensus Statement Ann Oncol 24 2013 647 654
10. L.J. van 't Veer, H. Dai, and M.J. van de Vijver et al. Gene expression profiling predicts clinical outcome of breast cancer Nature 415 2002 530 536
11. J.M. Bueno-de-Mesquita, W.H. van Harten, and V.P. Retel et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER) Lancet Oncol 8 2007 1079 1087
12. A. Goldhirsch, W.C. Wood, R.D. Gelber, A.S. Coates, B. Thurlimann, and H.J. Senn Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer J Clin Oncol 21 2003 3357 3365
13. Kwaliteitsinstituut voor de Gezondheidszorg CBO VvlK. Adjuvante Systemische Therapie voor het Operabel Mammacarcinoom. Richtlijn Behandeling van het Mammacarcinoom; 2004:46-70.
14. V.P. Retel, M.A. Joore, M. Knauer, S.C. Linn, M. Hauptmann, and W.H. Harten Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer Eur J Cancer 46 2010 1382 1391
15. A.H. Kamal, C.L. Loprinzi, and C. Reynolds et al. Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score Oncologist 16 2011 1359 1366
16. J.A. Foster, M. Abdolrasulnia, H. Doroodchi, J. McClure, and L. Casebeer Practice patterns and guideline adherence of medical oncologists in managing patients with early breast cancer J Natl Compr Canc Netw 7 2009 697 706
17. R. Mehta, R.K. Jain, and S. Badve Personalized medicine: the road ahead Clin Breast Cancer 11 2011 20 26
18. C.A. Drukker, J.M. Bueno-de-Mesquita, and V.P. Retel et al. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study Int J Cancer 133 2013 929 936
19. S. Aebi, T. Davidson, G. Gruber, and F. Cardoso Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 22 Suppl. 6 2011 vi12 vi24
20. A. Goldhirsch, W.C. Wood, A.S. Coates, R.D. Gelber, B. Thurlimann, and H.J. Senn Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 Ann Oncol 22 2011 1736 1747
21. G.C. Wishart, C.D. Bajdik, E. Dicks, E. Provenzano, M.K. Schmidt, and M. Sherman et al. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2 Br J Cancer 107 2012 800 807